Arda Therapeutics Secures $43M Series A Financing to Advance Targeted Cell Depletion Therapies

Arda Therapeutics Secures $43M Series A Financing to Advance Targeted Cell Depletion Therapies

Funding led by Andreessen Horowitz (a16z) Bio + Health, with participation from Two Sigma Ventures, RV Invest, Eli Lilly and Company, GV and other leading investors

Globally recognized R&D leader Scott Turner, Ph.D., joins Arda as chief scientific officer